Adlai Nortye ENA presentation. Adlai Nortye said on October 27, in a Form 6-K filing, that a late breaking abstract for AN4035, its first in class CEACAM5 targeting antibody drug conjugate carrying a pan RAS(ON) inhibitor payload, was selected for oral presentation at the EORTC-NCI-AACR symposium in Barcelona on November 19, 2026, including translational and EGFR combination data from its Phase 1 study. It is a presentation announcement, not new data. Source: Adlai Nortye via GlobeNewswire, October 27, 2026 (accession 0001213900-26-113051).
UK withdraws IXCHIQ chikungunya vaccine. The MHRA’s October safety roundup said the UK marketing authorisation for the IXCHIQ chikungunya vaccine has been withdrawn after a safety review concluded the benefit risk balance is no longer favourable, and clinicians should no longer prescribe or administer it. The same roundup implements new antidepressant safety measures, including a boxed warning in patient leaflets on suicidal thoughts and persistent sexual dysfunction. Source: UK MHRA, October 27, 2026.
Outpace Bio ends ovarian cell therapy trial. Endpoints News reported on October 27 that Seattle based Outpace Bio ended a Phase 1 cell therapy trial, dropping its mesothelin CAR-T program, in the same roundup that noted Genmab cutting its MCLA-129 program. No patient numbers were available in the reporting read. Source: Endpoints News, October 27, 2026.
Pantethine psoriasis signal. Genetic Engineering News reported a small human trial in which the vitamin derivative pantethine alleviated psoriasis symptoms. The trial is small and the item is carried as an early signal only, not as evidence of efficacy. Source: Genetic Engineering News, October 27, 2026.
Nabsys genomic mapping at ASHG. Genetic Engineering News reported that Nabsys linked cytogenetics and genomics to map hematologic cancers in work presented at the American Society of Human Genetics meeting. It is platform research, carried here for the diagnostics watch list. Source: Genetic Engineering News, October 27, 2026.
Nonprofit revives a shelved gene therapy. STAT’s Readout newsletter on October 27 reported that a nonprofit has resurrected a shelved gene therapy after the originating startup shut down, alongside its Pennsylvania Dutch country gene therapy reporting first noted in yesterday’s roundup. Detail beyond the headline was behind the STAT paywall in this run. Source: STAT, October 27, 2026.
Not repeated: Roche divarasib (covered October 26), Artiva wind down, Ferring Gameto, Novartis quarter and the Lilly Novo advertising ruling (all covered October 27), and the Ebola outbreak in DR Congo (covered October 27 in politics, including the nurse killing story).